Clinical Trial Update: Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for blinatumomab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: B-Cell Non Hodgkin Lymphoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-01-13